Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil for negative symptoms in schizophrenia
NCT00772005Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Sep 2008
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of armodafinil in schizophrenia (4 arms), sponsored by Cephalon, Inc. Primary endpoint: Mean Change in Negative Scale Scores From the Positive and Negative Syndrome Scale (PANSS) From Baseline to Endpoint at 24 weeks. Started Sep 2008; status: completed.
02
Drugs
armodafinil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00772005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772005.